Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

incobotulinumtoxinA

Known as: BoNT-A 
 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Botulinum Toxin Type ANeuromuscular AgentsNeurotoxins
INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT

Narrower (3)

NT 201Xeominbocouture

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity
ABSTRACT Introduction: Efficacy and safety of incobotulinumtoxinA in post‐stroke upper‐limb spasticity were studied. Methods… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated
Typically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) are administered at approximately 3-month… Expand
  • table 1
  • figure 1
  • table 2
Is this relevant?
2013
2013
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia
IncobotulinumtoxinA (Xeomin®, NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2013
2013
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous… Expand
  • table 2
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2013
2013
Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
BACKGROUND Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2012
2012
Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
BACKGROUND IncobotulinumtoxinA and onabotulinumtoxinA are effective treatments for glabellar frown lines, and a dose of 20 U is… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia
OBJECTIVE IncobotulinumtoxinA differs from available formulations in that it does not have accessory proteins… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2011
2011
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free… Expand
Is this relevant?
2011
2011
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE